美高梅附属上海市第四人民医院血管病中心主任，美高梅附属上海市第四人民医院血管病研究所所长，59599aa美高梅教授、博士生导师，美高梅附属上海市第四人民医院院士培养对象，美高梅附属上海市第四人民医院主任医师，美高梅附属上海市第四人民医院外科教研室名誉主任，美高梅附属上海市第四人民医院临床研究中心名誉主任，海军军医大学第一附属医院血管外科名誉主任，上海市血管系统疾病临床医学中心主任，全军血管外科专业委员会主任委员，全军血管外科研究所所长，中国医师协会腔内血管学专业委员会创始主委，国家科技奖获得者，全国道德模范提名奖获得者，享受国务院特殊津贴
Chief Director of Center for Vascular Disease, Shanghai Fourth People's Hospital, Tongji University; Chief Director of Institute of Vascular Disease, Shanghai Fourth People's Hospital, Tongji University; Professor of Tongji University Medical college; Professor of the promotion object of the academician of the Fourth People's Hospital of Shanghai affiliated to Tongji University, the chief physician of the Fourth People's Hospital of Shanghai affiliated to Tongji University, and the Honorary Director of the Department of Surgery of the Fourth People's Hospital of Shanghai affiliated to Tongji University, honorary Director, Center for Clinical Research, Shanghai Fourth People's Hospital, Tongji University, Honorary Director, Department of Vascular Surgery, First Affiliated Hospital, Naval Medical University, Honorary Director, Shanghai Clinical Center for vascular diseases, chairman of the Military Vascular Surgery Professional Committee, Director of the Military Vascular Surgery Research Institute, Founding Chairman of the endovascular professional committee of the Chinese Physicians Association, and winner of the National Science and Technology Award, the winner of the National Moral Model Nomination Award a special allowance from the State Council
在国内率先开展主动脉扩张性疾病微创腔内治疗，于1997年完成国内首例“腹主动脉瘤微创腔内隔绝术”，1998年成功完成国内首例 “胸主动脉瘤微创腔内隔绝术”，1998年完成国内首例“主动脉夹层微创腔内隔绝术”。2003年和2004年在国际上首次提出Endovascology（腔内血管学）的理论概念及主动脉夹层腔内隔绝术的“3N3V”新分型方法，2004年牵头完成我国首部《胸主夹层动脉瘤腔内隔绝术应用指南》。后来又相继率先在国内成功完成了主动脉弓区，升主动脉区夹层动脉瘤以及心脏主动脉瓣狭窄等重大疾病的腔内微创治疗。
2002年主编并出版我国第一部血管微创腔内治疗专著《血管腔内治疗学》，同年主持国家卫生部视听教材《腹主动脉瘤》制作，并获全军优秀电视教材一等奖；2006年《现代血管外科手术学》荣获华东地区第七届优秀教材、学术专著一等奖；2007年获得“上海市医学领军人才”称号、全军育才金奖，同年参加了卫生部规划教材的编写工作，被卫生部任命为国家医师资格考试命审题委员；2009年《新时期外科学及野战外科学课程的创新与实践》项目获得军队教学成果奖一等奖和国家教学成果二等奖。长期致力于“腔内血管学”学术理论的推广应用，1997年开办第一届全国血管外科主任腔内微创技术学习班，到今天已经发展成为以ENDOVASCOLOGY（腔内血管学）为原创品牌的国际化学术交流平台。2010年带领学科荣获国家级教学团队称号，并于2013年在国家教育部立项支持下，创建“血管病学”二级学科。同年个人荣获上海市教育年度新闻人物称号。
在军队临床高新技术重大项目的支持下研创出腹主动脉开窗型腔内移植物，解决了累及内脏分支动脉的腹主动脉瘤的微创腔内治疗难题；在国家“863”项目的支持下研发出国际首创的分支型腔内移植物（CASTOR），攻克了主动脉弓微创腔内治疗禁区，并牵头国内各家血管外科针对本中心研创的一体化单分支腔内移植物开展多中心前瞻性临床试验，且相关进展得到国际权威学术媒体Vascular News的密切关注和跟踪报道，2017年7月获CFDA批准上市；创用短段型腔内移植物治疗升主动脉夹层，在国际上率先攻克了升主动脉微创腔内治疗禁区，其研究成果发表于国际循环领域顶尖杂志J Am CollCardiol(影响因子19.9)；2011年完成国内第一例球扩式主动脉瓣膜微创腔内置换术（TAVI）, 2013年本中心作为国内首家TAVI手术中心参加Asia Pacific多中心前瞻性临床研究。同时，率先开展了主动脉扩张性疾病微创腔内治疗的系统研究并获得包括国家863计划，国家科技攻关计划、国家自然科学基金重点项目等40余项基金的支持，在疾病发生发展机制研究、腔内器具研发和腔内技术创新等方面均取得突破性进展，获得国家级发明和实用新型专利授权60余项，在J Am Coll Cardiol（影响因子19. 9）等国际SCI收录及国家核心期刊发表论文500余篇。出版国际、国内专著40余部。先后荣获包括国家科技进步奖二等奖，国家教育部科技进步奖一等奖，中华医学科技奖一等奖，军队医疗成果奖一等奖等在内的一系列重大成果奖励。
于2017年1月获得国家科技进步二等奖在北京人民大会堂受到习近平总书记亲切接见。
In 1997, the first case of “Abdominal aortic aneurysm endovascular exclusion” was performed in China, in 1998, the first minimally invasive endovascular graft exclusion for thoracic aortic aneurysm was successfully performed in China. In 1998, the first aortic dissection endovascular graft exclusion was performed in China. In 2003 and 2004, the concept of Endovascology and the new classification method of “3N3V” for endovascular aortic dissection were first proposed internationally, in 2004, we took the lead in completing the first guide of endovascular exclusion for thoracic aortic dissection in our country. In recent years, we have successfully completed the endovascular treatment of aortic arch, ascending aortic dissecting aneurysm and aortic stenosis in China.
In 2002, he edited and published our country's first monograph on endovascular therapy for minimally invasive vascular diseases, and in the same year, he presided over the production of the audio-visual textbook abdominal aortic aneurysm by the Ministry of Health, in 2006, Modern Vascular Surgery won the first prize of the 7th East China excellent textbook and academic monograph In 2007, he won the title of“Leading medical talents in Shanghai” and the Gold Award for Military Education. In the same year, he participated in the compilation of teaching materials for the Ministry of Health, and was appointed by the Ministry of Health as a member of the selection of questions for the national medical qualification examination In 2009, the project“Innovation and practice of new era surgery and field surgery curriculum” won the first prize of Military Teaching Achievement Award and the second prize of National Teaching Achievement Award. Long-term commitment to the“Endovascular” academic theory of the application of the promotion, in 1997 launched the First National Vascular Surgery Director of Intracavitary minimally invasive technology classes, today, it has developed into an international academic exchange platform with ENDOVASCOLOGY as its original brand. In 2010, he led the discipline to win the title of National Teaching Team, and in 2013, the Ministry of Education supported the establishment of“Vascular” secondary disciplines. In the same year, he won the title of Shanghai Education News Person of the year.
With the support of the military clinical high-tech project, the fenestration-type endovascular graft of abdominal aorta was developed, which solved the problem of minimally invasive endovascular treatment of abdominal aortic aneurysm arteries involving visceral branches With the support of national“863” project, the International First Branch endovascular graft (Castor) was developed, which overcame the forbidden area of minimally invasive endovascular treatment of aortic arch, and lead the domestic Vascular Surgery Center for the development of integrated single-branch intracavitary graft to carry out a multi-center prospective clinical trials, in July 2017, it was approved by the CFDA for the market, and the short-segment intracavitary graft was used to treat the aortic dissection, the study was published in Jam CollCardiol (impact factor 19.9) , a leading journal in the field of international circulationThe first minimally invasive transluminal aortic valve replacement (Tavi) was performed in China in 2011, and the center participated in the Asia Pacific multicenter prospective clinical study as the first Tavi Surgical Center in China in 2013. At the same time, it has pioneered systematic research on minimally invasive endovascular treatment of aortic dilatation disease and obtained National 863 Program, supported by more than 40 funds, including the National Science and technology research plan and the National Natural Science Foundation of China, breakthroughs have been made in the study of the mechanism of disease occurrence and development, the development of intravessel devices and the innovation of intravessel technology, More than 60 patents of national invention and utility model have been granted. More than 500 papers have been published in international SCI and national core journals such as Jam Coll Cardiol (impact factor 19.9) . Published more than 40 international and domestic monographs. The State Science and Technology Prizes has won a series of awards for major achievements, including the second prize of the National Academy of Sciences, the first prize of the Science and Technology Progress Award of the Ministry of Education, the first prize of the Chinese Medical Science and Technology Award, and the first prize of the Military Medical Achievement Award. In January 2017, he won the second prize of the State Scientific and technological progress award at the Great Hall of the people in Beijing
